human vascular umbilical endothelial vein cells huvecs  (Cell Applications Inc)

Journal: PLOS Computational Biology

Article Title: Uncertainty-aware traction force microscopy

doi: 10.1371/journal.pcbi.1013079

Figure Lengend Snippet: ( A ) Membrane labeling of HUVEC monolayers with CellMask. ( B ) Corresponding fluorescent bead image (beads of size 0.2 μ m ). Arrows indicate bead-related image artifacts ( C ) PIV-UQ displacement field u PIV ( D ) PIV-UQ uncertainty map, σ u , P I V . White regions indicate “bad” PIV windows that were deleted and replaced as described in § 2.2. Uncertainty arrows denote the pointwise angular uncertainty corresponding to 1 circular std. dev. of bootstrapped PIV-UQ distribution. ( E ) Inferred mean marginal posterior traction stress, t ^ ( F ) Marginal posterior traction stress uncertainty field ( σ t ). Uncertainty arrows denote the pointwise angular uncertainty corresponding to 1 circular std. dev. of marginal posterior p ( t | u h ) . Scale bar : 25 μ m

Article Snippet: Human vascular umbilical endothelial vein cells (HUVECs) (Cell Applications) were cultured in M199 (Gibco) supplemented with 10 % (v/v) endothelial growth medium (Cell Applications), 10 % (v/v) fetal bovine serum (Gibco), and 1 % penicillin-streptomycin (Gibco).

Techniques: Membrane, Labeling

Journal: Pharmaceutics

Article Title: Development of an Ophthalmic Hydrogel to Deliver MG53 and Promote Corneal Wound Healing †

doi: 10.3390/pharmaceutics17040526

Figure Lengend Snippet: rhMG53 inhibits vascular endothelial cell migration and tube formation. ( A ) rhMG53 did not induce cellular toxicity in HUVEC up to 100 μg/mL ( n = 5; ** p = 0.01). ( B ) Representative photomicrographs 24 h after scratch wounding, HUVEC treated with 50 μg/mL rhMG53 had significantly less migration and proliferation compared to control ( n = 9). Magnification 4×. ( C ) Quantification of the scratch area remaining at 24 h (**** p < 0.0001). ( D ) Representative photomicrographs and quantification of tube formation when HUVEC was seeded on Matrigel, followed by treatment with VEGF (10 ng/mL) with or without rhMG53 (50 μg/mL) for 18 h. rhMG53 significantly reduced tube length in VEGF-treated HUVEC ( n = 4; ** p = 0.0029). Magnification 4×. ( E ) HUVEC treated with IL-1B (10 ng/mL) with or without rhMG53 have decreased pSTAT3 protein expression; when normalized to total STAT3 expression, rhMG53 significantly (** p = 0.0084) decreased pSTAT3 ( n = 4). Statistical significance was assessed with the Kruskal–Wallis nonparametric test.

Article Snippet: Normal primary human vascular endothelial cells (HUVEC) were purchased from ATCC (Manassas, VA, USA) and grown in F-12K medium containing endothelial cell growth supplement.

Techniques: Migration, Control, Expressing